Lancy Co.,Ltd. News

Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the

Zhitong FinanceApr 23 18:16

Langzi Co., Ltd. (002612): Performance is in line with expectations, and the company continues to grow with high quality

國泰君安Apr 23 15:06

Langzi Co., Ltd. (002612): Medical and aesthetic revenue increased 28% in '23, profitability recovered year on year

中金公司Apr 23 11:46

Langzi Co., Ltd. (002612): Endogenous extension simultaneously helps medical and aesthetic growth and nurtures stores are expected to gradually reduce losses

中信建投證券Apr 23 11:26

Langzi Co., Ltd. (002612): Net profit due to mother increased 953% in 2023, medical and aesthetic business further expanded the chain layout

國信證券Apr 23 10:31

Langzi Co., Ltd. (002612): The medical and aesthetic business is growing well, profitability is improving, and the nationwide layout is accelerating

開源證券Apr 23 00:00

Langzi Co., Ltd. (002612): Steady endogenous and epitaxial expansion, continuous release of performance flexibility

國泰君安Apr 20 00:00

Langzi Co., Ltd. (002612): Proposed acquisition of Jimei, Zhengzhou to continue to accelerate the national layout of medical and aesthetic business

廣發證券Mar 1 07:41

Review of the Langzi Co., Ltd. (002612) incident: Proposed acquisition of Jimei, Zhengzhou, further the national layout

信達證券Feb 29 18:22

Langzi Co., Ltd. (002612): Proposed to acquire 100% of the shares in Jimei, Zhengzhou, and acquire medical and aesthetic mergers and acquisitions

中金公司Feb 29 07:32

Langzi Co., Ltd. (002612): Net profit due to mother is expected to increase 836% in 2023

國信證券Jan 31 07:21

Langzi Co., Ltd. (002612) Company Information Update Report: Net profit to the mother is expected to increase 836%-1070% in 2023, and the acquisition of hospitals successfully completed performance commitments

開源證券Jan 30 15:16

Langzi Co., Ltd. (002612) 23-year performance forecast review: The performance of the three major businesses is improving, and we expect the national layout of medicine and aesthetics to continue to improve

信達證券Jan 30 00:00

Langzi Co., Ltd. (002612): Outstanding performance growth in 2023, new acquirers deliver on performance promises

國聯證券Jan 29 00:00

Langzi Co., Ltd. (002612): Beautiful management, high profit, continuous enrichment of medical and aesthetic matrices

首創證券Nov 20, 2023 20:02

Langzi Co., Ltd. (002612): Net profit growth was good in 2023Q3, and continued efforts to reduce costs and increase efficiency

開源證券Nov 15, 2023 15:26

Langzi Co., Ltd. (002612): Apparel and Aesthetic Medicine Are Recovering Rapidly, Profitability Is Gradually Restoring

廣發證券Nov 14, 2023 18:12

Langzi Co., Ltd. (002612) Review: Steady revenue, high profit, impressive growth rate of medical and aesthetic business after the epidemic

申萬宏源研究Nov 1, 2023 19:22

Langzi Co., Ltd. (002612): Q3 performance continues to increase, profitability continues to be optimized

東北證券Oct 31, 2023 18:07

Langzi Co., Ltd. (002612): Maintaining Profitability and Continued Verification of the Industrial Fund Model

中信建投證券Oct 31, 2023 11:02